TY - JOUR
T1 - Liquid Biopsy-Guided Interventional Oncology: A Proof of Concept with a Special Focus on Radiotherapy and Radiology
AU - Malara, N.
AU - Kovacs, G.
AU - Bussu, F.
AU - Ferrazzo, T.
AU - Garo, V.
AU - Raso, C.
AU - Cornacchione, Patrizia
AU - Iezzi, Roberto
AU - Tagliaferri, Luca
PY - 2022
Y1 - 2022
N2 - Although the role of liquid biopsy (LB) to measure minimal residual disease (MRD) in the treatment of epithelial cancer is well known, the biology of the change in the availability of circulating biomarkers arising throughout treatments such as radiotherapy and interventional radio-oncology is less explained. Deep knowledge of how therapeutic effects can influence the biology of the release mechanism at the base of the biomarkers available in the bloodstream is needed for selecting the appropriate treatment-induced tumor circulating biomarker. Combining existing progress in the LB and interventional oncology (IO) fields, a proof of concept is provided, discussing the advantages of the traditional risk assessment of relapsing lesions, limitations, and the timing of detection of the circulating biomarker. The current review aims to help both interventional radiologists and interventional radiation oncologists evaluate the possibility of drawing a tailor-made board of blood-based surveillance markers to reveal subclinical diseases and avoid overtreatment.
AB - Although the role of liquid biopsy (LB) to measure minimal residual disease (MRD) in the treatment of epithelial cancer is well known, the biology of the change in the availability of circulating biomarkers arising throughout treatments such as radiotherapy and interventional radio-oncology is less explained. Deep knowledge of how therapeutic effects can influence the biology of the release mechanism at the base of the biomarkers available in the bloodstream is needed for selecting the appropriate treatment-induced tumor circulating biomarker. Combining existing progress in the LB and interventional oncology (IO) fields, a proof of concept is provided, discussing the advantages of the traditional risk assessment of relapsing lesions, limitations, and the timing of detection of the circulating biomarker. The current review aims to help both interventional radiologists and interventional radiation oncologists evaluate the possibility of drawing a tailor-made board of blood-based surveillance markers to reveal subclinical diseases and avoid overtreatment.
KW - CTCs
KW - cancer
KW - ct-DNA
KW - interventional oncology
KW - liquid biopsy
KW - minimal residual disease
KW - radiotherapy
KW - CTCs
KW - cancer
KW - ct-DNA
KW - interventional oncology
KW - liquid biopsy
KW - minimal residual disease
KW - radiotherapy
UR - https://publicatt.unicatt.it/handle/10807/227571
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85139937040&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85139937040&origin=inward
U2 - 10.3390/cancers14194676
DO - 10.3390/cancers14194676
M3 - Article
SN - 2072-6694
VL - 14
SP - N/A-N/A
JO - Cancers
JF - Cancers
IS - 19
ER -